PharmaShots | Incisive News in 3 Shots

Subscribe Now

XELJANZ

Pfizer's Xeljanz (tofacitinib citrate) Receives EC's Approval for the Treatment of Active Polyarticular JIA & Juvenile PsA

Pfizer's Xeljanz (tofacitinib citrate) Receives EC's Approval for the Treatment of Active Polyarticular JIA & Juvenile PsA

August 23, 2021

Insights+: The US FDA New Drug Approvals in September 2020

Insights+: The US FDA New Drug Approvals in September 2020

October 15, 2020

Pfizer's Xeljanz (tofacitinib) Receives the US FDA's Approval for Active Polyarticular Course Juvenile Idiopathic Arthritis

Pfizer's Xeljanz (tofacitinib) Receives the US FDA's Approval for Active Polyarticular Course Juvenile Idiopathic Arthritis

September 29, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us